Annual Cash & Cash Equivalents
$178.69 M
+$45.33 M+33.99%
December 31, 2024
Summary
- As of March 10, 2025, TCRX annual cash & cash equivalents is $178.69 million, with the most recent change of +$45.33 million (+33.99%) on December 31, 2024.
- During the last 3 years, TCRX annual cash & cash equivalents has risen by +$17.28 million (+10.71%).
- TCRX annual cash & cash equivalents is now at all-time high.
Performance
TCRX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$178.69 M
+$45.57 M+34.23%
December 31, 2024
Summary
- As of March 10, 2025, TCRX quarterly cash and cash equivalents is $178.69 million, with the most recent change of +$45.57 million (+34.23%) on December 31, 2024.
- Over the past year, TCRX quarterly cash and cash equivalents has stayed the same.
- TCRX quarterly cash and cash equivalents is now -26.21% below its all-time high of $242.16 million, reached on June 30, 2024.
Performance
TCRX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
TCRX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +34.0% | 0.0% |
| 3 y3 years | +10.7% | 0.0% |
| 5 y5 years | +327.9% | 0.0% |
TCRX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +48.9% | -26.2% | +86.9% |
| 5 y | 5-year | at high | +413.6% | -26.2% | +413.6% |
| alltime | all time | at high | +413.6% | -26.2% | +413.6% |
TScan Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $178.69 M(+34.0%) | $178.69 M(+34.2%) |
| Sep 2024 | - | $133.12 M(-45.0%) |
| Jun 2024 | - | $242.16 M(+72.3%) |
| Mar 2024 | - | $140.51 M(+5.4%) |
| Dec 2023 | $133.36 M(+11.1%) | $133.36 M(-14.1%) |
| Sep 2023 | - | $155.19 M(-25.7%) |
| Jun 2023 | - | $208.84 M(+118.4%) |
| Mar 2023 | - | $95.61 M(-20.3%) |
| Dec 2022 | $120.03 M | $120.03 M(-12.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $137.31 M(+9.3%) |
| Jun 2022 | - | $125.60 M(-10.8%) |
| Mar 2022 | - | $140.84 M(-12.7%) |
| Dec 2021 | $161.41 M(+363.9%) | $161.41 M(-11.5%) |
| Sep 2021 | - | $182.31 M(+71.7%) |
| Jun 2021 | - | $106.20 M(-12.6%) |
| Mar 2021 | - | $121.50 M(+249.2%) |
| Dec 2020 | $34.79 M(-16.7%) | - |
| Dec 2020 | - | $34.79 M |
| Dec 2019 | $41.76 M | - |
FAQ
- What is TScan Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for TScan Therapeutics?
- What is TScan Therapeutics annual cash & cash equivalents year-on-year change?
- What is TScan Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for TScan Therapeutics?
- What is TScan Therapeutics quarterly cash and cash equivalents year-on-year change?
What is TScan Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of TCRX is $178.69 M
What is the all time high annual cash & cash equivalents for TScan Therapeutics?
TScan Therapeutics all-time high annual cash & cash equivalents is $178.69 M
What is TScan Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, TCRX annual cash & cash equivalents has changed by +$45.33 M (+33.99%)
What is TScan Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of TCRX is $178.69 M
What is the all time high quarterly cash and cash equivalents for TScan Therapeutics?
TScan Therapeutics all-time high quarterly cash and cash equivalents is $242.16 M
What is TScan Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, TCRX quarterly cash and cash equivalents has changed by $0.00 (0.00%)